A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf.
Immune Checkpoint Inhibition, the Key to Success in Renal Cell Carcinoma?
2019
Kidney Cancer
Preserved Fulltext
Treatment of renal cell carcinoma (RCC) has evolved rapidly since the development of checkpoint inhibitors. Most of the studies have been conducted in patients with metastatic disease and led to a significant change in the treatment landscape. Currently, many studies are investigating immune checkpoint inhibition (ICI) in the neoadjuvant and adjuvant setting and the efficacy of combination therapies. It remains difficult to predict which patients will respond best. Consequently, there is a high
doi:10.3233/kca-190065
fatcat:zvdpvq24yrcxnksfsdno3huvmu